Court Ruled for Teva and Apotex in Patent Case

The District of Delaware ruled that generic drug labels for tasimelteon do not infringe upon Vanda Pharmaceuticals patents.

Updated on Oct. 1, 2026 in Healthcare

Bold flat-color editorial illustration showing a geometric grid of featureless white pharmaceutical capsules on a navy background, representing legal clarity in patent regulation. — The District of Delaware ruled in favor of Teva and Apotex, affirming that generic drug labels do not infringe upon Vanda Pharmaceuticals' patents. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies be held responsible for off-label uses of their medications by patients?

The District of Delaware granted summary judgment to Teva and Apotex, determining that their generic versions of HETLIOZ do not infringe on Vanda Pharmaceuticals patents. The court held that labels describing drug interaction risks are not affirmative steps toward patent infringement.

Why it matters

The ruling clarifies that simply including standard drug interaction language in generic product labels does not constitute evidence of encouraged patent infringement. This decision reinforces the legal standard for generic pharmaceutical labeling and market access.

Teva and Apotex filed their generic Abbreviated New Drug Applications in 2018 for the 20 mg dosage of HETLIOZ. The patents involved in the legal dispute are currently slated to expire in 2033.

The players

Teva Pharmaceuticals USA, Inc.

A major global pharmaceutical company that specializes in the production of generic and specialty medications.

Apotex

A Canadian-based pharmaceutical firm that develops, manufactures, and distributes generic drugs worldwide.

Vanda Pharmaceuticals Inc.

A biopharmaceutical company that focuses on the development and commercialization of therapies for central nervous system disorders.

The details

The court relied on the precedent set by Hikma v. Amarin to determine that the generic manufacturers did not engage in affirmative conduct to promote a method of treatment protected by Vanda patents. Evidence presented demonstrated that patients frequently use beta blockers alongside these generic products, supporting the finding of substantial non-infringing use.

HETLIOZ 20 mg capsules were initially approved in 2014.
Teva and Apotex received FDA approval for their generic ANDAs in December 2022.
The Supreme Court established the affirmative-conduct standard in Hikma v. Amarin on June 4, 2026.
Remaining counterclaims in the case are set for trial in October 2026.
Patents listed for HETLIOZ reach their expiration in 2033.

Market Landscape

This ruling follows the legal pattern established by the Supreme Court decision in Hikma v. Amarin regarding the interpretation of generic labeling requirements. By limiting the scope of induced infringement claims, the court provides generic manufacturers greater stability when entering the market.

The decision supports the continued availability of generic HETLIOZ alternatives for patients in Delaware and nationwide. Increased market competition from generic versions often leads to more affordable medication options for consumers.

The takeaway

This case illustrates how courts are increasingly applying narrow standards to determine what constitutes encouraging patent infringement by generic makers. For stakeholders, it underscores the importance of the Hikma precedent in shaping the future of pharmaceutical market competition.